Interaction of St John's wort with conventional drugs: systematic review of clinical trials

被引:80
作者
Mills, E
Montori, VM
Wu, P
Gallicano, K
Clarke, M
Guyatt, G
机构
[1] McMaster Univ, Dept Clin Epidemiol & Biostat, McMaster Hlth Sci Ctr, Hamilton, ON L8N 3Z5, Canada
[2] Mayo Clin Coll Med, Dept Med, Rochester, MN 55905 USA
[3] London Sch Hyg & Trop Med, London WC1E 7HU, England
[4] Watson Labs, Corona, CA 92878 USA
[5] UK Cochrane Ctr, Oxford OX2 7LG, England
来源
BRITISH MEDICAL JOURNAL | 2004年 / 329卷 / 7456期
关键词
D O I
10.1136/bmj.329.7456.27
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Objective To determine the methodological quality of clinical trials that examined possible interactions of St John's wort with conventional drugs, and to examine the results of these trials. Design Systematic review. Data sources Electronic databases from inception to April 2004, reference lists from published reports, and experts in the field. Study selection Eligible studies were prospective clinical trials evaluating the pharmacokinetic effect of St John's wort on the metabolism of conventional drugs. Data extraction Two reviewers selected studies for inclusion and independently extracted data. Data synthesis 22 pharmacokinetic trials studied an average of 12, (SD 5) participants; 17 trials studied healthy volunteers and five studied patients. Most (17) studies used a "before and after" design; four studies used control groups other than the active group. Three studies randomised the sequence of administration or the participants to study arms or periods; three studies blinded participants or investigators. In 15 trials, investigators independently assayed the herb. of 19 trials with available plasma data, three found no important interaction (change in area under the curve <20%) and 17 found a decrease in systemic bioavailability of the conventional drug; in seven studies the 95% confidence interval excluded a decrease of <20%. Conclusion Clinicians and patients should beware of possible decreases in the systemic bioavailability of conventional drugs when taken concomitantly with St John's wort.
引用
收藏
页码:27 / 30
页数:4
相关论文
共 29 条
[1]
Altman D. G., 2000, Statistics with Confidence, P28
[2]
Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John's wort in renal transplant patients [J].
Bauer, S ;
Störmer, E ;
Johne, A ;
Krüger, H ;
Budde, K ;
Neumayer, HH ;
Roots, I ;
Mai, I .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (02) :203-211
[3]
Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers [J].
Burstein, AH ;
Horton, RL ;
Dunn, T ;
Alfaro, RM ;
Piscitelli, SC ;
Theodore, W .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) :605-612
[4]
Draves Andrew H, 2003, Can J Clin Pharmacol, V10, P114
[5]
Coordinate induction of both cytochrome P4503A and MDRI by St John's wort in healthy subjects [J].
Dresser, GK ;
Schwarz, UI ;
Wilkinson, GR ;
Kim, RB .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (01) :41-50
[6]
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4 [J].
Dürr, D ;
Stieger, B ;
Kullak-Ublick, GA ;
Rentsch, KM ;
Steinert, HC ;
Meier, PJ ;
Fattinger, K .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (06) :598-604
[7]
*FOOD DRUG ADM, 1999, IN VIVO DRUG MET DRU
[8]
The interaction between St John's wort and an oral contraceptive [J].
Hall, SD ;
Wang, ZQ ;
Huang, SM ;
Hamman, MA ;
Vasavada, N ;
Adigun, AQ ;
Hilligoss, JK ;
Miller, M ;
Gorski, JC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (06) :525-535
[9]
St. John's wort: A systematic review of adverse effects and drug interactions for the consultation psychiatrist [J].
Hammerness, P ;
Basch, E ;
Ulbricht, C ;
Barrette, EP ;
Foppa, I ;
Basch, S ;
Bent, S ;
Boon, H ;
Ernst, E .
PSYCHOSOMATICS, 2003, 44 (04) :271-282
[10]
Effects of St. John's Wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers [J].
Hebert, ME ;
Park, JM ;
Chen, YL ;
Akhtar, S ;
Larson, AM .
JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (01) :89-94